Raze Therapeutics, a leading next-generation cancer metabolism company, announced today the appointment of Mark Manfredi, Ph.D., as Chief Scientific Officer. Dr. Manfredi joins Raze with nearly two decades of experience in cancer biology, having served most recently as Vice President, Oncology Biology at Takeda Pharmaceuticals.
